Kentucky First Federal Bancorp (KFFB) said Friday its board will hold a special meeting on July 28 to consider the resumption of its dividend, which the company has not paid since November 2023.
The board of directors will review the declaration of a quarterly dividend of up to $0.10 per share. It could also decide to declare a lower dividend or no dividend at all.
Shares rose nearly 5% in recent afternoon trading.
Price: $4.77, Change: $+0.21, Percent Change: +4.68%
(Updates with Allied Gold's comment in the last paragraph.)Hong Kong-listed Zijin Gold International's $4 billion takeover of Canada's Allied Gold (AAUC) is facing delays because of opposition from Beijing regulators, the Financial Times reported Friday, citing people familiar with the matter.China's National Development and Reform Commission questioned the premium Zijin is paying, as well as the geopolitical risks associated with Allied's gold mine in Mali, the report said.The agreement had a closing deadline of Friday, which can be extended if both sides agree, the report said."There is strong industrial and commercial logic for this transaction, and both parties continue to work diligently towards closing," Allied said in an emailed statement to.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $26.01, Change: $-1.17, Percent Change: -4.30%
XPeng (XPEV) shares were up nearly 1% in Friday trading after Macquarie upgraded the stock to outperform from neutral.Trading volume stood at over 5.1 million shares, compared with a daily average of roughly 7 million.Price: $16.56, Change: $+0.11, Percent Change: +0.70%
Johnson & Johnson (JNJ) said Friday that updated Phase 1/1b CHRYSALIS-2 data showed Rybrevant plus Lazcluze achieved a median overall survival of 41 months in patients with advanced non-small cell lung cancer with atypical epidermal growth factor receptor mutations.The company said the results add to the evidence showing potential of this combination to deliver durable survival outcomes in both common and atypical EGFR-mutated advanced NSCLC in the first-line setting.The company said the combination previously demonstrated a 57% objective response rate and showed consistent clinical activity across atypical EGFR mutation subgroups.Price: $224.71, Change: $-6.09, Percent Change: -2.64%